公开(公告)号：EP4338803A3

公开(公告)日：2024-10-09

申请号：EP23177290.6

申请日：2014-05-09

申请人： Quince Therapeutics S.p.A.

发明人： MAMBRINI, Giovanni ,  BENATTI, Luca ,  CAPOGROSSI, Giovanni ,  MANDOLINI, Marco

IPC分类号： A61K9/50 ,  A61K35/18 ,  A61P9/14 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06 ,  A61K31/661 ,  A61K38/45 ,  C12N5/078

CPC分类号： A61K9/5089 ,  A61K35/18 ,  A61K9/5068 ,  A61K31/661 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06 ,  A61P9/14 ,  C12N5/0641

摘要： The present invention relates to a process for preparing erythrocytes loaded with one or more substance of pharmaceutical interest. The present invention is also directed to loaded erythrocytes thus obtained and pharmaceutical compositions comprising said population of loaded erythrocytes as well as therapeutic application thereof, in particular in the treatment of Ataxia telangiectasia.

公开(公告)号：EP3820455B1

公开(公告)日：2024-06-19

申请号：EP19736745.1

申请日：2019-07-10

IPC分类号： A61K9/50

CPC分类号： A61K9/5073 ,  A61K9/5089

公开(公告)号：EP4380552A1

公开(公告)日：2024-06-12

申请号：EP22744319.9

申请日：2022-07-12

申请人： Stabican B.V.

发明人： DE BRUIJN, Robin

IPC分类号： A61K9/50 ,  A61K47/10 ,  A61K47/14 ,  A61P21/00 ,  A61P21/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/26 ,  A61K31/122 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/465 ,  A61K31/485 ,  A61K31/59

CPC分类号： A61K9/5015 ,  A61K9/5089 ,  A61P21/04 ,  A61P21/00 ,  A61P25/06 ,  A61P25/08 ,  A61P25/26

公开(公告)号：EP4355307A2

公开(公告)日：2024-04-24

申请号：EP22736011.2

申请日：2022-06-12

申请人： Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

发明人： BENNY, Ofra ,  AMOYAV, Ben Zion

IPC分类号： A61K9/16 ,  A61K31/135 ,  A61K31/704 ,  A61K49/04 ,  A61K9/50 ,  A61K9/00 ,  A61K31/13 ,  A61K31/70 ,  A61K9/19

CPC分类号： A61K9/5031 ,  A61K9/5089 ,  A61K9/19 ,  A61K9/0019 ,  A61P35/00 ,  A61K9/5052 ,  A61K9/5057 ,  A61K9/5036 ,  A61K9/1641 ,  A61K9/1647 ,  A61K9/1635 ,  A61K49/048 ,  A61K31/53 ,  A61K31/136 ,  A61K31/407 ,  A61L24/04 ,  A61L24/001 ,  A61L2430/3620130101 ,  A61L24/046 ,  A61L2400/1220130101 ,  A61L24/0015 ,  A61L24/0036

公开(公告)号：EP3411022A2

公开(公告)日：2018-12-12

申请号：EP17748023.3

申请日：2017-01-31

申请人： Emory University ,  Georgia Tech Research Corporation ,  Chapman University ,  Children's Healthcare of Atlanta, Inc.

发明人： LAM, Wilbur A. ,  HANSEN, Caroline ,  SAKURAI, Yumiko ,  LYON, Andrew

IPC分类号： A61K9/50 ,  A61K9/62 ,  A61K38/36 ,  A61K38/37 ,  C07K14/75 ,  C07K14/745 ,  C07K14/755

CPC分类号： A61K9/5073 ,  A61K9/0019 ,  A61K9/5052 ,  A61K9/5089 ,  A61K38/37

摘要： This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.

公开(公告)号：EP3154523B1

公开(公告)日：2018-11-21

申请号：EP15741328.7

申请日：2015-06-15

申请人： VALPHARMA INTERNATIONAL S.P.A.

发明人： VALDUCCI, Roberto ,  AVANESSIAN, Serozh

IPC分类号： A61K9/16 ,  A61K9/50 ,  A61K31/606

CPC分类号： A61K31/606 ,  A61K9/0053 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1688 ,  A61K9/2081 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5089

摘要： The present invention relates to a formulation containing Mesalazine in a stable form, obtained by coating the starting core with a first membrane in non-aqueous solution; said core containing Mesalazine at a high concentration, greater than 90%, obtained by producing starting cores with Active Substance content greater than 97%. The formulation according to the present invention containing Mesalazine with specific release in the colon; in particular the capsule formulation containing 500 mg of Mesalazine with specific release in the colon.

公开(公告)号：EP3390483A1

公开(公告)日：2018-10-24

申请号：EP16860652.3

申请日：2016-10-26

申请人： The Procter & Gamble Company

发明人： ZHANG, Hanwei ,  SCHWANTES, Todd, Arlin ,  HOBART, Katie, Ann ,  WILLIAMSON, Diane, Jean

IPC分类号： C08G18/62 ,  C08F2/32 ,  B01J13/14 ,  A61K8/11 ,  C08F220/06 ,  C08J9/32 ,  B01J13/16 ,  C08F2/22 ,  B01J13/02 ,  A61K9/50

CPC分类号： A61K9/5031 ,  A01N25/28 ,  A61K8/11 ,  A61K8/8152 ,  A61K8/87 ,  A61K8/88 ,  A61K9/50 ,  A61K9/5026 ,  A61K9/5089 ,  A61K2800/412 ,  A61L15/225 ,  A61L15/46 ,  A61L15/60 ,  A61Q5/02 ,  A61Q13/00 ,  A61Q15/00 ,  A61Q17/04 ,  A61Q19/10 ,  B01J13/14 ,  B01J13/16 ,  B01J13/18 ,  C09B67/0097 ,  C10M171/06 ,  C10N2220/08 ,  C10N2250/16 ,  C11D3/505 ,  C11D17/0039 ,  F28D20/023

摘要： An improved process of making a benefit agent delivery particle and consumer products incorporating such particles are disclosed. The process comprises the steps of providing a first composition of water phase 1, water phase 2 and water phase 3. Water phase 1 comprises water and an initiator; water phase 2 comprises water, a water-soluble or dispersible amine(meth)acrylate or hydroxyl(meth)acrylate and a multifunctional (meth)acrylate. Water phase 3 comprises water, and carboxyalkyl(meth)acrylate and a base or quarternary ammonium acrylate. The first two water phases are combined to prereact the hydroxy- or amine(meth)acrylate and the multifunctional (meth)acrylate to form a multifunctional hydroxyl-amine(meth)acrylate pre-polymer. The pre-polymer is combined with water phase 3; then an emulsion is formed by emulsifying under high shear agitation a second composition into said first composition; said second composition comprising an oil phase comprising an isocyanate and a benefit agent core material thereby forming a wall surrounding the benefit agent core material.

公开(公告)号：EP2059558B1

公开(公告)日：2018-10-24

申请号：EP07802136.7

申请日：2007-09-05

申请人： DSM IP Assets B.V.

发明人： ARMES, Steven ,  YUAN, Jian-Jun

IPC分类号： C08K3/36 ,  A61K9/50 ,  C08K9/00

CPC分类号： A61K9/5089 ,  A61K9/501 ,  C08K3/36 ,  C08K9/00 ,  C08K9/02 ,  C08K9/10 ,  C08K9/12 ,  C08K2201/011 ,  C08K2201/013 ,  C08L53/00 ,  C08L2207/53 ,  C09D7/70 ,  G02B1/111 ,  Y10T428/254 ,  Y10T428/2998

摘要： The invention provides a composition comprising core-shell nanoparticles, the nanoparticles comprising (a) cationic core material comprising polymer; and (b) a shell material comprising silica. Preferred core materials comprise diblock copolymer micelles comprising one block of dialkylaminoethyl methacrylate units which are partially or fully quaternised and one block of dialkylaminoethyl methacrylate units that remain non-quaternised . The invention also provides a method for the preparation of the said composition, the method involving (a) preparing a cationic core material comprising polymer; and (b) coating the core material with a shell comprising silica by treating the polymer with a silica precursor under ambient conditions. The invention also envisages a composition comprising core-shell nanoparticles which is adapted to facilitate controlled delivery of at least one active agent into a system in response to controlled changes in the pH of the system.

公开(公告)号：EP3009130B1

公开(公告)日：2018-10-10

申请号：EP15195081.3

申请日：2011-08-02

申请人： SOFAR S.p.A.

发明人： LABRUZZO, Carla

IPC分类号： A61K9/50 ,  A61K31/573 ,  A61P1/04

CPC分类号： A61K9/5078 ,  A61K9/1676 ,  A61K9/5089 ,  A61K31/573

摘要： The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres consist of: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present disclosure also refers to a process for obtaining said compositions.

公开(公告)号：EP3373978A1

公开(公告)日：2018-09-19

申请号：EP16865170.1

申请日：2016-11-11

申请人： Graybug Vision, Inc.

发明人： YU, Yun ,  KAYS, Joshua ,  YANG, Ming ,  CLELAND, Jeffrey, L.

IPC分类号： A61K47/50 ,  A61K9/14 ,  A61K9/50

CPC分类号： A61K9/5089 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/1641 ,  A61K9/1647 ,  A61K9/5026 ,  A61K9/5031 ,  A61K31/404 ,  A61K47/10 ,  A61K47/26 ,  A61K47/36

摘要： The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.